CoChat

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

Open access
Maggioni, Aldo P, Anand, Inder, Gottlieb, Sidney O, Latini, Roberto, Tognoni, Gianni, Cohn, Jay N · 2002 · Journal of the American College of Cardiology

The DOI matches its Crossref record; 21 of the 23 references it cites were found in a registry or an index.

Abstract

Objectives A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the patients with chronic heart failure (HF) not receiving angiotensin-converting enzyme (ACE) inhibitors.Background The ACE inhibitors reduce mortality and morbidity in patients with HF. Nonetheless, nearly 20% of potentially eligible patients may not be prescribed ACE inhibitors.Results Val-HeFT was an international, randomized, double-blinded trial that compared valsartan with placebo when added to the prescribed treatment of patients with HF. The two primary end points of the study were all-cause mortality and the composite of all-cause mortality and morbidity (sudden death with resuscitation, hospital admission for HF, or administration of intravenous inotropic or vasodilator drugs for >or=4 h without hospital admission). Of the 5,010 patients enrolled in the trial, 366 (7.3%) were not treated with ACE inhibitors at baseline. The effects of valsartan on the primary and secondary end points of the study were assessed in this subgroup of patients.Results Both all-cause mortality and combined mortality and morbidity for patients not treated with ACE inhibitors were significantly reduced in the valsartan treatment group compared with the placebo group (17.3% vs. 27.1%, p = 0.017 and 24.9% vs. 42.5%, p < 0.001, respectively). Consistent with the data on clinical events, patients randomized to valsartan showed improvements in physiologic variables, such as ejection fraction, left ventricular internal diameter in diastole, and plasma neurohormone levels. Permanent discontinuation of study treatment because of adverse experiences was comparable between the two groups.Conclusions Val-HeFT has provided the first placebo-controlled outcome data demonstrating a favorable effect of an angiotensin receptor blocker on mortality and morbidity in patients with HF not treated with ACE inhibitors. Based on these results, valsartan appears to be an effective therapy in ACE inhibitor-intolerant patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0735-1097(02)02304-5

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 356

Metadata

Authors
Maggioni, A. P., Anand, I., Gottlieb, S. O., Latini, R., Tognoni, G., & Cohn, J. N.
Affiliations
  • Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
  • Minneapolis VA Medical Center (US)
  • Mario Negri Institute for Pharmacological Research (IT)
  • University of Minnesota (US)
Corresponding author
Maggioni, Aldo P
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2002-10
Volume
40
Issue
8
Pages
1414-1421
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2110831147
Cited by
356
References
23
Citations by year
2026: 5 · 2025: 2 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 14 · 2020: 10 · 2019: 10 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 14
FWCI
18.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
valsartan, chronic heart failure, angiotensin receptor blockers, ACE inhibitors, ACE inhibitor intolerance, Val-HeFT trial, all-cause mortality, heart failure morbidity, ejection fraction, neurohormones, subgroup analysis
MeSH terms
Valsartan, Aged, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Female, Heart Failure, Humans, Male, Middle Aged, Quality of Life, Tetrazoles, Valine, Randomized Controlled Trials as Topic, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. https://app.cochat.ai/papers/10.1016/s0735-1097(02)02304-5
The paper
Maggioni, A. P., Anand, I., Gottlieb, S. O., Latini, R., Tognoni, G., & Cohn, J. N. (2002). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(02)02304-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.